Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Safe Baby Products Act

This article was originally published in The Tan Sheet

Executive Summary

Sen. Kirsten Gillibrand, D-N.Y., introduces S. 295 to direct FDA to investigate cosmetics and personal care marketed to and used by children, according to April 29 release. The bill also would require FDA "to test a wide range of children's personal-care products, publicly report the findings and establish good manufacturing practices to reduce or eliminate hazardous contaminants from products." The legislation responds to the Campaign for Safe Cosmetics' "Toxic Tub" report, which analyzed and identified children's products containing suspected carcinogens 1,4-dioxane and formaldehyde. At the time of the report's release, Gillibrand said she would explore legislation to have FDA more closely scrutinize baby products (1"The Rose Sheet" March 23, 2009, p. 3). Sens. Dianne Feinstein, D-Calif., and Charles Schumer, D-N.Y., are co-sponsors

You may also be interested in...



More “Toxic Tub” Fallout: Senator Gillibrand Decries “Total Lack Of Oversight”

Sen. Kirsten Gillibrand, D-N.Y., is the latest Democrat to speak out about what she perceives as "a complete and total lack of oversight" in the personal-care sector, based on findings from the Campaign for Safe Cosmetics "Toxic Tub" report

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel